Vaccination against human papilloma virus in mensituation and proposals

  1. Javier Cortés 1
  2. Ángel Gil 2
  3. Federico Martinón 36
  4. Francisco Xavier Bosch 47
  5. José Manuel Ramón y Cajal 5
  1. 1 Royal Academy of Medicine of the Balearic Islands.
  2. 2 Rey Juan Carlos University.
  3. 3 Pediatric Service. University Clinical Hospital of Santiago de Compostela.
  4. 4 Institute Catalá Oncología
    info

    Institute Catalá Oncología

    Barcelona, España

    ROR https://ror.org/01j1eb875

  5. 5 Gynecology Service. Hospital of San Jorge, Huesca
  6. 6 Group of Genetics, Vaccines, Infections and Pediatrics. Sanitary Research Institute of Santiago de Compostela.
  7. 7 Universitat Oberta de Catalunya
    info

    Universitat Oberta de Catalunya

    Barcelona, España

    ROR https://ror.org/01f5wp925

Mostrar afiliacións +
Revista:
Academic Journal of Health Sciences: Medicina Balear

ISSN: 2255-0560

Ano de publicación: 2022

Volume: 37

Número: 3

Páxinas: 166-170

Tipo: Artigo

DOI: 10.3306/AJHS.2022.37.03.166 DIALNET GOOGLE SCHOLAR lock_openIbdigital editor

Resumo

Se describe la epidemiología causal de la patología papiloma virus causal en el hombre y su incidencia y la situación de su actividad preventiva en España, no conforme con la recomendación que la evidencia científica ha formulado y que numerosos países de nuestro entorno sí están siguiendo. Se detallan líneas de acción al respecto que se consideran preferentes desde el punto de vista de acción político – sanitaria.

Referencias bibliográficas

  • Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM et al.: High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001; 10: 101-6
  • Available in https://www.who.int/es/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis) Access 01.08.2021.
  • Castellsagué X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX et al.: Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study. J Med Virol. 2012; 84: 947-56.
  • Spanish Society of Epidemiology. Papilloma Virus and Cancer. Available in:https://www.seepidemiologia.es/documents/dummy/4monografiaVirusPapilomaYCancer.pdf. Access 02.08.2021
  • Szymonowicz KA, Chen J.: Biological and clinical aspects of HPV-related cancers Cancer Biol Med. 2020; 17: 864-78.
  • Available in:https://www.aecc.es/es/todo-sobre-cancer/que-es-cancer/factores-riesgo Access 02.08.2021.
  • López, N, Torné A, Franco A, San-Martín, M, Viayna E, Barrull C et al.: Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine. Infect Agent Cancer. 2018; 13: 15.
  • Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-9.
  • Ghebreyesus TA, Director General.: Reunión Ejecutiva OMS Intercontinental Hotel, Genève, Confédération Suisse. 19 May 2018.
  • Cortés J, Bosch X, Concha A, González A, Martinón F, Ortiz de Lejarazu R et al.: Asociación Española contra el Cáncer: Documento de posición sobre prevención del Cáncer de Cuello de Útero. Prog Obstet Ginecol 2019; 61: 510-44.
  • Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee J-H et al.: The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2036-43
  • Ingles DJ, Lin HY, Fulp WJ, Sudenga SL, Lu B, Schabath MB et al.: An analysis of HPV infection incidence and clearance by genotype and age in men: The HPV Infection in Men (HIM) Study. Papillomavirus Res 2015; 1: 126-35
  • Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S.: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202: 1789-99.
  • Giuliano AR, Lee J-H, Fulp W, Villa LL, Lazcano-Ponce E, Papenfuss MR, Abrahamsen M et al.: Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377: 932-40.
  • Albero G, Villa LL, Lazcano-Ponce E, Fulp W, Papenfuss MR, Nyitray AG et al.: Male circumcision and prevalence of genital human papillomavirus infection in men: a multinational study. BMC Infect Dis. 2013; 13: 18.
  • Chatuverdi AK, Engels EA, Pfeiffer RM, Hernández BY, Weihong X, Kim E et al.: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29: 4294-301.
  • Giuliano AR, Viscidi R, Torres N, Ingles DJ, Sudenga SL, Villa LL et al.: Seroconversion Following Anal and Genital HPV Infection in Men: The HIM Study. Papillomavirus Res. 2015; 1: 109-15.
  • Stanley M.: Program Research Epidemiology of Cancer. Cambridge Univ. Presented at EUROGIN 2018. 2-5 December. Lisbon. Portugal.
  • Cervarix® summary product characteristics. Available in https://cima.aemps.es/cima/dochtml/ft/07419004/FT_07419004.html Access 03.08.2021.
  • Gardasil9® summary product characteristics. Available in https://cima.aemps.es/cima/dochtml/ft/1151007002/FT_1151007002.html Access 03.08.2021.
  • Available in: https://search.usa.gov search?query=gardasil9+expanded&affiliate=fda1 Access 03.07.2021
  • Global Advisory Committee on Vaccine Safety (GACVS). Weekly Epidemiological Record: 92; 28. 14 de julio de 2017.
  • Majed L, Bresse X, El Mouaddin N, Schmidt A, Daniels VJ, Pavelyev et al.: Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. Vaccine. 2021; 39: 438-46.
  • Simons JJM, Vida N, Westra TA, Postma MJ.: Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. Vaccine. 2020; 38: 4687-94.
  • Qendri V, Bogaards JA, Baussano I, Lazzarato F, Vänskä S, Berkhof J.: The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. Lancet Public Health. 2020; 5: e592 – e603.
  • Vänskä S, Luostarinen T, Baussano I, Apter D, Eriksson T, Natunen K et al.: Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. J Infect Dis. 2020; 222: 948-56.
  • Available in https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/vacunas/profesionales/vph.htm Access 27.08.2021.
  • Available in:https://vacunasaep.org/profesionales/noticias/VPH-informe-ECDC-vacunacion-varones-y-otros-temas Access 03.08.2021.
  • European Commission. Europe’s Beating Cancer Plan. Communication from the Commission to the European Parliament and the Council 2021. Available in: https://ec.europa.eu/health/sites/default/files/non_communicable_diseases/docs/eu_cancer-plan_en.pdf Access 27.08.2021
  • Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G.: Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009; 27: 127-47.
  • Available in: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/coberturas/docs/Tabla11.pdf) Access 03.08.2021.
  • K Pollock (2019). Adolescent male vaccination in the United Kingdom - a victory for equality. www.HPVWorld.com, 94.
  • Linertová R, Guirado Fuentes C, Toledo Chávarri A, Vallejo Torres L, García Pérez L, Delgado Rodríguez J et al.: Vacuna frente a VPH en varones adolescentes: coste-efectividad e impacto presupuestario. Ministry of Health, Consumption and Social Welfare. Evaluation Service of the Canary Islands Health Service; 2020. Health Technology Assessment Reports.
  • Available in https://www.euskadi.eus/informacion/vacuna-contra-el-virus-del-papiloma/web01-a2adik/es/ Access 10.09.2021
  • Available in:https://saludcantabria.es/index.php?page=vacunaciones Access 10.09.2021
  • Available in:https://salutpublica.gencat.cat/web/.content/minisite/aspcat/promocio_salut/vacunacions/00manual_de_vacunacions/capitols_i_annexos_manual/apartat_4_vacunes_disponibles/Manual-Vacunacions-apartat-4_12.pdf Access 11.09.2021
  • Available in:https://www.saludcastillayleon.es/es/vacunaciones/vacunacion-frente-virus-papiloma-humano-vph-2019 Access 11.09.2021
  • Available in https://www.who.int/news/item/22-07-2021-vaccine-inequity-undermining-global-economic-recovery Access 02.09.2021.
  • Colzani E, Johansen K, Johnson H, Celentano LP.: Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma. Euro Surveill. 2021; 26(50).
  • Lehtinen M, Baussano I, Paavonen J, Vänska S, Dillner J.: Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies. Expert Rev Vaccines. 2019; 18: 153 – 160.
Fonte de datos: Dialnet